Jiyoung Rhee

Jiyoung Rhee

Auto-generated profile, based on publicly available information

Jiyoung Rhee

Division of Hematology-Oncology, Department of Internal Medicine, Jeju National University Hospital, Jeju, Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JRJiyoung Rhee
Jiyoung Rhee
SHSae-Won Han
Sae-Won Han
DODo-Youn Oh
Do-Youn Oh
JKJee Hyun Kim
Jee Hyun Kim
SISeock-Ah Im
Seock-Ah Im
TKTae-You Kim
Tae-You Kim
Background: Triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2), represents a subset of breast cancer with different biologic behaviour. We investigated the clinicopathologic characteristics and prognostic indicators of lymph node-negative TN breast cancer. Methods: Medical records were reviewed from patients with node-negative breast cancer who underwent curative surgery at Seoul National University Hospital between Jan. 2000 and Jun. 2003. Clinicopathologic variables and clinical outcomes were evaluated. Results: Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast cancer. TN breast cancer correlated with younger age (< 35 y, p = 0.003), and higher histologic and nuclear grade (p < 0.001). It also correlated with a molecular profile associated with biological aggressiveness: negative for bcl-2 expression (p < 0.001), positive for the epidermal growth factor receptor (p = 0.003), and a high level of p53 (p < 0.001) and Ki67 expression (p < 0.00). The relapse rates during the follow-up period (median, 56.8 months) were 14.7% for TN breast cancer and 6.6% for non-TN breast cancer (p = 0.004). Relapse free survival (RFS) was significantly shorter among patients with TN breast cancer compared with those with non-TN breast cancer (4-year RFS rate 85.5% vs. 94.2%, respectively; p = 0.001). On multivariate analysis, young age, close resection margin, and triple-negativity were independent predictors of shorter RFS. Conclusion: TN breast cancer had higher relapse rate and more aggressive clinicopathologic characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be integrated into the risk factor analysis for node-negative breast cancer.

1 January 2012 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
BEB.W. Eom
B.W. Eom
HYH.M. Yoon
H.M. Yoon
KRK.W. Ryu
K.W. Ryu
JLJ.H. Lee
J.H. Lee
SCSoo-Jeong Cho
Soo-Jeong Cho
YKYoung-Woo Kim
Young-Woo Kim

9 July 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YCYoung Kwang Chae
Young Kwang Chae
SKSung Koo Kang
Sung Koo Kang
MKMyoung Sook Kim
Myoung Sook Kim
JWJanghee Woo
Janghee Woo
JLJuna Lee
Juna Lee
CMChulso Moon
Chulso Moon
Aquaporins (AQPs) have previously been associated with increased expression in solid tumors. However, its expression in hematologic malignancies including CML has not been described yet. Here, we report the expression of AQP5 in CML cells by RT-PCR and immunohistochemistry. While normal bone marrow biopsy samples (n = 5) showed no expression of AQP5, 32% of CML patient samples (n = 41) demonstrated AQP5 expression. In addition, AQP5 expression level increased with the emergence of imatinib mesylate resistance in paired samples (p = 0.047). We have found that the overexpression of AQP5 in K562 cells resulted in increased cell proliferation. In addition, small interfering RNA (siRNA) targeting AQP5 reduced the cell proliferation rate in both K562 and LAMA84 CML cells. Moreover, by immunoblotting and flow cytometry, we show that phosphorylation of BCR-ABL1 is increased in AQP5-overexpressing CML cells and decreased in AQP5 siRNA-treated CML cells. Interestingly, caspase9 activity increased in AQP5 siRNA-treated cells. Finally, FISH showed no evidence of AQP5 gene amplification in CML from bone marrow. In summary, we report for the first time that AQP5 is overexpressed in CML cells and plays a role in promoting cell proliferation and inhibiting apoptosis. Furthermore, our findings may provide the basis for a novel CML therapy targeting AQP5.

1 March 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SPS R Park
S R Park
SKS-Y Kong
S-Y Kong
BNB-H Nam
B-H Nam
ICI J Choi
I J Choi
CKC G Kim
C G Kim
NKN K Kim
N K Kim
We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin. Among MGC patients (n=108), who received S-1 (40 mg m−2 b.i.d., days 1–14) and cisplatin (60 mg m−2, day 1) every 3 weeks, we analysed the wild-type allele (W) and variants (V) of CYP2A6 (*4, *7, *9, *10), and the polymorphisms of ERCC1 (rs11615, rs3212986) and XRCC1 (rs25487). Patients having fewer CYP2A6 variants had better response rates (W/W vs W/V other than *1/*4 vs V/V or *1/*4=66.7 vs 58.3 vs 32.3%; P=0.008), time to progression (TTP) (7.2 vs 6.1 vs 3.5 months, P=0.021), and overall survival (23.2 vs 15.4 vs 12.0 months, P=0.004). ERCC1 19442C>A (rs3212986) was also associated with response rate (C/C, 46.7% vs C/A, 55.3% vs A/A, 87.5%) (P=0.048) and TTP (4.4 vs 7.6 vs 7.9 months) (P=0.012). Patients carrying both risk genotypes of CYP2A6 (V/V or 1/*4) and ERCC1 19442C>A (C/C) vs those carrying none showed an adjusted odds ratio of 0.113 (P=0.004) for response, and adjusted hazard ratios of 3.748 (P=0.0001) for TTP and 2.961 (P=0.006) for death. Polymorphisms of CYP2A6 and ERCC1 19442C>A correlated with the efficacy of S-1/cisplatin.

24 August 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
JRJiyoung Rhee
Jiyoung Rhee
SHSae‐Won Han
Sae‐Won Han
DODo‐Youn Oh
Do‐Youn Oh
SISeock‐Ah Im
Seock‐Ah Im
TKTae‐You Kim
Tae‐You Kim
YBYung‐Jue Bang
Yung‐Jue Bang

22 September 2010 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SPS. R. Park
S. R. Park
SKS.-Y. Kong
S.-Y. Kong
JRJ. Rhee
J. Rhee
YPY.-I. Park
Y.-I. Park
KRK. W. Ryu
K. W. Ryu
NKN. K. Kim
N. K. Kim
Background: The aim of this study was to investigate the efficacy and safety of S-1/irinotecan/oxaliplatin (TIROX) in metastatic gastric cancer (MGC) and the association between treatment outcome and uridine diphosphate-glucuronosyltransferase (UGT) 1A polymorphisms. Patients and methods: Patients with previously untreated MGC received S-1 40 mg/m2 b.i.d. on days 1–14 and irinotecan 150 mg/m2 plus oxaliplatin 85 mg/m2 on day 1 every 3 weeks. Results: Forty-four patients were enrolled. In intent-to-treat analysis, the objective response rate was 75%, including the complete response (CR) rate of 14%. The median time to progression and overall survival was 10.2 and 17.6 months, respectively. Ten (26%) of the 39 patients with primary gastric tumor showed biopsy-confirmed gastric CR. Grade 3/4 neutropenia developed in 66% of patients and grade 3 febrile neutropenia in 16%. The most common grade 3 nonhematologic toxic effects were abdominal pain (18%), anorexia (16%), and diarrhea (14%). UGT1A polymorphisms were associated with significantly higher incidence of grade 4 leukopenia (UGT1A1*6), neutropenia (UGT1A1*6, UGT1A6*2, and UGT1A7*3), grade 3/4 febrile neutropenia (UGT1A1*6), and grade 3 abdominal pain (UGT1A1*6). Conclusions: The TIROX regimen induced marked tumor reduction and promising survival with a manageable toxicity profile in MGC patients. UGT1A genotype may be predictive of TIROX toxicity.